June 30, 2016
Recommended Topic Related To:

Surfaxin

"On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need f"...

A A A

Surfaxin




PATIENT INFORMATION

No information provided. Please refer to the WARNINGS AND PRECAUTIONS sections.

Last reviewed on RxList: 3/16/2012
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.